Hims & Hers to offer at-home blood draws, lean into ‘peptide innovations' with new acquisitions
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
Hims & Hers Health (HIMS) Projected to Post Quarterly Earnings on Monday
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Hims & Hers Buys Lab to Expand Into At-Home Blood Testing
Hims & Hers Health Inc. is expanding beyond its successful foray into providing copycat weight-loss drugs with the ...
Business Wire4d
Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
Hims & Hers Health, Inc., the leading health and wellness platform, today announced its plans to introduce at-home lab ...
Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...
Hims & Hers Health (NYSE:HIMS) Sees Large Volume Increase After Analyst Upgrade
Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) saw unusually-high trading volume on Friday after Bank of America raised their price target on the stock from $18.00 to $21.00. Bank of ...